Pegylated Opioids with Low Potential for Abuse

• US 20110237614A1
• Filed: 09/16/2009
• Published: 09/29/2011
• Est. Priority Date: 09/16/2008
• Status: Abandoned Application

• Current Assignee: Nektar Therapeutics Incorporated
• Original Assignee: Nektar Therapeutics Incorporated
• Inventors: Zacarias, Alberto N., Jude-Fishburn, C. Simone, Gursahani, Hema, Riley, Timothy A.
• Application Number:
  US13/063,919
• Publication Number:
  US 20110237614A1
• Time in Patent Office: Days
• US Class Current: 514/282
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/36 Opioid-abuse
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides opioid agonists covalently bound to a water-soluble oligomer having reduced potential for substance abuse and uses thereof. The compounds of the invention possess altered pharmacokinetic profiles relative to the opioid agonists alone, but are not subject to the risk of physical tampering that allows for the recovery and abuse of the opioid agonist associated with certain alternative delivery formulations.

Claims

1. A compound of the formula:

OP-X-POLY

wherein OP is an opioid compound, X is a linker, and POLY is a small water-soluble oligomer.

2. The compound according to claim 1 wherein OP is selected from the group consisting of fentanyl, hydromorphone, methadone, morphine, codeine, oxycodone, and oxymorphone.

3. The compound according to claim 1 wherein X is a stable linker.

4. The compound according to claim 3 wherein POLY is a small PEG moiety.

5. The compound according to claim 4 wherein the PEG moiety consists of 1-5 ethylene glycol subunits.

6. The compound according to claim 4 wherein the PEG moiety consists of 1-3 ethylene glycol subunits.

7. The compound according to claim 3 having a log P of about 1.0 to about 3.5.

8. The compound according to claim 3 wherein the compound has a log P about 0.5 units more negative than that of OP.

9. The compound according to claim 3 wherein OP-X-POLY binds to an OP target receptor that is the same target receptor to which OP in its unconjugated form binds.

10. The compound according to claim 9 which exhibits a less than about a 10-fold loss of affinity of OP-X-POLY for the OP target receptor relative to the affinity of OP to its target receptor.

11. The compound according to claim 9 wherein the reduction in affinity of OP-X-POLY for the OP target receptor is no greater than 20% relative to the affinity of OP to its target receptor.

12. The compound according to claim 3 wherein OP-X-POLY retains at least 10% bioactivity relative to the bioactivity of unconjugated OP.

13. The compound according to claim 12 wherein OP-X-POLY retains at least 50% bioactivity relative to the bioactivity of unconjugated OP.

14. The compound according to claim 3 wherein OP-X-POLY exhibits less than about a 10-fold decrease in bioactivity relative to the bioactivity of unconjugated OP.

15. The compound according to claim 1 wherein the molecular weight of the compound is less than 1000 Daltons.

16. The compound according to claim 1 wherein the molecular weight of X-POLY is less than 1000 Daltons.

17. The compound according to claim 1, having a blood-brain barrier crossing rate that is less than the rate of blood-brain barrier crossing of OP alone.

18. The compound according to claim 17, having a blood-brain barrier crossing rate that is at least 50% less than the rate of OP alone.

19. The compound according to claim 17, having a blood-brain barrier crossing rate that is at least 75% less than the rate of OP alone.

20. The compound of claim 3, having a blood-brain barrier crossing rate that is at least 10-fold less than the blood-brain barrier crossing rate of OP alone.

21. The compound of claim 1, wherein X is a physiologically cleavable linker.

22. The compound according to claim 21 wherein POLY is a small PEG moiety consisting of at least 6 polyethylene glycol subunits.

23. The compound according to claim 21 wherein OP-X-POLY exhibits greater than about a 10-fold decrease in bioactivity relative to unconjugated OP.

24. The compound of claim 21 wherein OP-X-POLY retains less than 5% of the bioactivity of unconjugated OP.

25. The compound of claim 24 wherein OP-X-POLY retains less than 2% of the bioactivity of unconjugated OP.

26. The compound of claim 21, having at least about a 10-fold loss of affinity for its target receptor relative to the affinity of unconjugated OP for the same OP target receptor.

27. A composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient or carrier.

28. A method of treating a patient in need of opioid therapy comprising administering an effective amount of a compound of claim 1.

29. A method of reducing the abuse potential of an opioid compound comprising conjugating the compound to a small water-soluble oligomer to form a compound of claim 1.

30. A method of reducing the addictive properties of an opioid agonist comprising conjugating the opioid agonist to a small water-soluble oligomer to form a compound of claim 1.

33. Use of a compound of claim 1 for treating a patient in need of opioid therapy.

34. Use of a compound of claim 1 for the manufacture of a medicament for reducing the abuse potential of the opioid compound, OP.

31. A method of reducing, but not substantially eliminating, the rate of crossing the blood brain barrier of an opioid compound comprising conjugating the compound to a small water-soluble oligomer.

32. A prodrug comprising a mu, kappa, or delta opioid agonist reversibly attached via a covalent bond to a releasable moiety, wherein a given molar amount of the prodrug administered to a patient exhibits a rate of accumulation and a C_max of the mu, kappa, or delta opioid agonist in the central nervous system in the mammal that is less than the rate of accumulation and the C_max of an equal molar amount of the mu, kappa, or delta opioid agonist had the mu, kappa, or delta opioid agonist not been administered as part of a prodrug.

35. Use of a prodrug comprising a mu, kappa, or delta opioid agonist reversibly attached via a covalent bond to a releasable moiety for achieving a rate of accumulation and a C_max of the mu, kappa, or delta opioid agonist in the central nervous system of a mammal to whom a given molar amount of prodrug is administered that is less than the rate of accumulation and the C_max of an equal molar amount of the mu, kappa, or delta opioid agonist when administered to the mammal in non-prodrug form.